trastuzumab-deruxtecan modulates her2 breast cancer cell fate and immune microenvironment
Published 1 month ago • 27 plays • Length 21:16Download video MP4
Download video MP3
Similar videos
-
5:59
trastuzumab deruxtecan for the treatment of her2 breast cancer
-
1:12
trastuzumab deruxtecan in metastatic her2 breast cancer
-
2:12
trastuzumab deruxtecan in her2-low advanced breast cancer | nejm
-
8:42
trastuzumab deruxtecan in her2 breast cancer
-
1:29
tuxedo-1: trastuzumab deruxtecan for the treatment of her2-positive breast cancer brain metastases
-
5:26
trastuzumab deruxtecan shows benefit in patients with her2 mbc
-
5:09
trastuzumab deruxtecan shows benefit across her2 metastatic breast cancer subgroups
-
2:15
treatment strategies for her2 metastatic breast cancer
-
0:59
the significance of her2 expression for the activity of trastuzumab deruxtecan
-
5:40
trastuzumab deruxtecan doubles pfs in metastatic breast cancer with low her2 expression
-
7:15
characterizing the immune microenvironment before and following anti-her2 neoadjuvant therapy
-
1:05
efficacy of trastuzumab deruxtecan in her2-low metastatic breast cancer
-
4:01
trastuzumab deruxtecan: a promising agent for treating her2-low breast cancer?
-
2:04
breast cancer chess championship: trastuzumab vs her2 receptor
-
0:22
targeted therapies for breast cancer: a breakthrough in treatment
-
0:34
future role of immunotherapy in her2 breast cancer
-
3:43
evolving role of trastuzumab deruxtecan in her2 /her2-low mbc
-
10:40
inb03 and lapatinib reverses resistance to trastuzumab in her2 breat cancer in pre-clinical models.
-
1:12
her2climb-04: tucatinib trastuzumab deruxtecan in her2 breast cancer